share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K:重大事件
美股SEC公告 ·  06/05 17:17
Moomoo AI 已提取核心信息
On June 3, 2024, Mangoceuticals, Inc., a company listed on the Nasdaq Capital Market under the trading symbol MGRX, reported significant corporate activities through a Form 8-K filing with the SEC. The company issued 192,308 shares of restricted common stock to a third-party consultant for professional relations and consulting services, with an agreement lasting until May 23, 2025. The consultant will also receive $15,000 monthly and additional stock compensation after six and nine months of service. These transactions are exempt from registration under the Securities Act due to the private nature of the offering and the accredited status of the recipient. Furthermore, Mangoceuticals granted 1,250,000 fully-vested shares to certain officers, an employee, and directors as part of their 2022 Equity Plan. CEO and Chairman Jacob D. Cohen received the largest share allocation with 800,000 shares. The equity awards are a bonus for services rendered in 2024. The company's actions reflect its ongoing compensation strategy and commitment to its executive team and board members.
On June 3, 2024, Mangoceuticals, Inc., a company listed on the Nasdaq Capital Market under the trading symbol MGRX, reported significant corporate activities through a Form 8-K filing with the SEC. The company issued 192,308 shares of restricted common stock to a third-party consultant for professional relations and consulting services, with an agreement lasting until May 23, 2025. The consultant will also receive $15,000 monthly and additional stock compensation after six and nine months of service. These transactions are exempt from registration under the Securities Act due to the private nature of the offering and the accredited status of the recipient. Furthermore, Mangoceuticals granted 1,250,000 fully-vested shares to certain officers, an employee, and directors as part of their 2022 Equity Plan. CEO and Chairman Jacob D. Cohen received the largest share allocation with 800,000 shares. The equity awards are a bonus for services rendered in 2024. The company's actions reflect its ongoing compensation strategy and commitment to its executive team and board members.
2024年6月3日,纳斯达克资本市场上市的Mangoceuticals股票代码MGRX的公司通过向SEC提交8-K文件披露了重要的公司活动。该公司发行了192,308股限制性普通股给第三方咨询服务专业人士,协议持续到2025年5月23日。咨询师在服务六个月和九个月后还将获得15,000美元每月以及额外的股票报酬。这些交易由于发行的私密性和接收方的资格而免于根据证券法进行注册。此外,Mangoceuticals根据其2022年股权计划向某些高管、员工和董事授予了1,250,000股完全归属的股票。CEO兼董事长Jacob D. Cohen获得最多的股票配额为800,000股。这些股权奖励是服务2024年的奖励。该公司的行动反映了其持续的补偿策略以及对其执行团队和董事会成员的承诺。
2024年6月3日,纳斯达克资本市场上市的Mangoceuticals股票代码MGRX的公司通过向SEC提交8-K文件披露了重要的公司活动。该公司发行了192,308股限制性普通股给第三方咨询服务专业人士,协议持续到2025年5月23日。咨询师在服务六个月和九个月后还将获得15,000美元每月以及额外的股票报酬。这些交易由于发行的私密性和接收方的资格而免于根据证券法进行注册。此外,Mangoceuticals根据其2022年股权计划向某些高管、员工和董事授予了1,250,000股完全归属的股票。CEO兼董事长Jacob D. Cohen获得最多的股票配额为800,000股。这些股权奖励是服务2024年的奖励。该公司的行动反映了其持续的补偿策略以及对其执行团队和董事会成员的承诺。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息